OptimizeRx Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Lang James Paul, was filed 19 Mar 2025.
OptimizeRx Corp: what insiders have been doing
OptimizeRx Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 7 insiders have disclosed 35 filings since 24 October 2025.
Only sales appear on the open market, 1 sale in all totalling €16k, filed by 1 insider. Biggest ticket of the year: €16k, sold by Stelmakh Edward and made public on 22 December 2025.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (3,167 companies, median 24 filings), a count of 35 filings is above the norm. The full history, which starts in 2010, counts 70 purchases against 86 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 109.4 m USD and net income at 5.1 m USD.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- -31.9%Entry US$8.79 · Close at T+365 US$5.99
- +150.7%Entry US$5.23 · Close at T+365 US$13.11
- -46.3%Entry US$15.87 · Close at T+365 US$8.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 414 shares@ US$8.390.0022% mcap8.4% of flowCommon StockSEC:0001628280-26-064386:0
- 57,600 shares0Common StockSEC:0001628280-26-058670:0
- 57,600 shares0Common StockSEC:0001628280-26-058669:0
- 1,243 shares@ US$7.710.0065% mcap24.5% of flowCommon StockSEC:0001628280-26-058584:0
- 57,600 shares0Common StockSEC:0001628280-26-058672:0
- 1,020 shares@ US$7.710.0053% mcap36.2% of flowCommon StockSEC:0001628280-26-058589:0
- 1,529 shares@ US$7.710.0080% mcap7.5% of flowCommon StockSEC:0001628280-26-058586:0
- 1,381 shares@ US$7.710.0072% mcap8.4% of flowCommon StockSEC:0001628280-26-058583:0
- 1,737 shares@ US$7.710.0091% mcap1.0% of flowCommon StockSEC:0001628280-26-058588:0
- 79,200 shares0Common StockSEC:0001628280-26-058673:0
- 1,386 shares@ US$9.233.6% of flowCommon StockSEC:0001628280-26-007972:1
- 4,000 sharesCommon StockSEC:0001628280-26-007972:0
- 5,237 shares0Common StockSEC:0001628280-25-058715:0
- 4,079 shares@ US$12.7464.3% of flowCommon StockSEC:0001628280-25-058761:0
- 1,420 shares@ US$12.7428.8% of flowCommon StockSEC:0001628280-25-058770:0
- 4,051 shares@ US$12.7432.6% of flowCommon StockSEC:0001628280-25-058763:0
- 3,658 shares@ US$12.7436.7% of flowCommon StockSEC:0001628280-25-058758:0
- 3,361 shares@ US$12.740.037% mcap3.1% of flowCommon StockSEC:0001628280-25-058799:0
- 581 shares@ US$13.517.3% of flowCommon StockSEC:0001628280-25-058408:1
- 1,388 shares@ US$13.514.1% of flowCommon StockSEC:0001628280-25-058413:1
- 1,594 shares@ US$13.510.3% of flowCommon StockSEC:0001628280-25-058412:1
- 1,153 shares@ US$13.514.4% of flowCommon StockSEC:0001628280-25-058411:1
- 6,546 shares0Common StockSEC:0001628280-25-058412:0
- 3,928 shares0Common StockSEC:0001628280-25-058411:0
- 289 shares@ US$13.5117.9% of flowCommon StockSEC:0001628280-25-058410:0
25 of 476 declarations
About OptimizeRx Corp
OptimizeRx Corp. (Nasdaq: OPRX) is a U.S.-listed healthcare technology company traded on the NASDAQ Capital Market in the United States. For French, Belgian and Swiss investors, the company sits at the intersection of healthcare, software, and pharmaceutical marketing. Headquartered in Waltham, Massachusetts, OptimizeRx was founded in 2006. Its business is centered on a technology platform that helps life sciences companies better reach and engage healthcare professionals (HCPs) and patients in a market shaped by regulation, data privacy requirements, and workflow integration. ([investors.optimizerx.com](https://investors.optimizerx.com/investor-relations))
OptimizeRx originally built solutions around coupons, co-pay assistance, and patient support delivered through electronic health record and e-prescribing workflows. Over time, the company evolved into a broader digital health and commercial engagement platform, combining software, data, analytics, and targeted activation capabilities. The acquisition of Medicx Health expanded the company’s consumer-focused omnichannel reach and strengthened its ability to connect HCP and direct-to-consumer strategies within a single privacy-safe framework. ([optimizerx.com](https://www.optimizerx.com/about-us?utm_source=openai))
Read moreShow less
Today, its main business lines include point-of-care solutions, in-workflow clinical messaging, audience activation, patient targeting, and privacy-safe omnichannel marketing. OptimizeRx emphasizes an AI-enabled approach designed to deliver timely, relevant messages at the moment of care and to improve treatment access and decision-making. From a competitive standpoint, the company differentiates itself through its embedded presence in EHR/eRx channels, its ability to connect brands with both providers and consumers, and its positioning as a commercial technology partner to pharmaceutical and broader life sciences budgets. ([investors.optimizerx.com](https://investors.optimizerx.com/investor-relations))
Geographically, OptimizeRx is primarily focused on the United States, which is the natural market for its point-of-care and pharmaceutical engagement model given the structure of U.S. prescribing, healthcare workflows, and healthcare advertising rules. The company serves a national base of pharmaceutical and life sciences clients from its Waltham, Massachusetts headquarters. Recent communications also point to continued network expansion, strategic renewals, and deeper ecosystem partnerships. ([investors.optimizerx.com](https://investors.optimizerx.com/static-files/261cfad9-d91a-4bde-a9da-dfd3276f0075))
Recent developments have been constructive. In second-quarter 2025 results, OptimizeRx reported 55% revenue growth to $29.2 million, higher gross profit, a return to GAAP profitability, and increased full-year 2025 guidance. Management also highlighted stronger contracted revenue, continued free-cash-flow generation, and accelerated debt repayment. For investors, the key takeaway is an improving profile of profitable growth, although the company remains exposed to customer concentration and the spending patterns of pharmaceutical marketers. ([investors.optimizerx.com](https://investors.optimizerx.com/static-files/261cfad9-d91a-4bde-a9da-dfd3276f0075))
